BIOCRYST PHARMACEUTICALS INC (BCRX)
US09058V1035 - Common Stock
| MRQ (2024-9-30) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 96.84M | 110.64M | 304.80M | 504.40M | 272.10M | |||
| Marketable Securities | 233.17M | 278.34M | 119.50M | 3.20M | 28.20M | |||
| Receivables | 72.46M | 56.95M | 50.60M | 29.40M | 8.60M | |||
| Inventories | 7.56M | 28.68M | 27.50M | 15.80M | 7.00M | |||
| Other Current Assets | 17.09M | 21.35M | 14.10M | 13.30M | 7.70M | |||
| Total Current Assets | 427.13M | 495.97M | 516.50M | 566.10M | 323.80M | |||
| Non-Current Assets | ||||||||
| PPE Net | 7.42M | 20.91M | 15.40M | 15.20M | 10.90M | |||
| Investments And Advances | 19.43M | 0.00 | 18.10M | 6.80M | N/A | |||
| Other Non-Current Assets | 37.28M | 80.00K | N/A | N/A | N/A | |||
| Total Non-Current Assets | 64.13M | 20.99M | 33.50M | 22.10M | 10.90M | |||
| TOTAL ASSETS | 491.25M | 516.96M | 550.00M | 588.20M | 334.70M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 30.00M | |||
| Current Portion Of LT Debt. | 34.84M | 25.16M | N/A | N/A | 0.00 | |||
| Accrued Expenses | 105.25M | 103.94M | 89.90M | 74.50M | 56.80M | |||
| Accounts Payable | 13.48M | 20.89M | 14.40M | 27.80M | 18.70M | |||
| Other Current Liabilities | N/A | 0.00 | 1.20M | 1.40M | 200.00K | |||
| Total Current Liabilities | 153.57M | 149.99M | 105.50M | 103.70M | 105.70M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 798.18M | 814.11M | 733.30M | 585.50M | 244.50M | |||
| Other Non-Current Liabilities | 8.06M | 8.39M | 5.80M | 6.00M | 3.90M | |||
| Total Non-Current Liabilities | 806.25M | 822.50M | 739.10M | 591.40M | 248.30M | |||
| TOTAL LIABILITIES | 959.82M | 972.49M | 844.60M | 695.10M | 354.00M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -1.74B | -1.68B | -1.45B | -1.21B | -1.02B | |||
| Additional Paid In Capital | 1.27B | 1.22B | 1.16B | 1.10B | 1.00B | |||
| Common Shares | 2.07M | 2.06M | 1.90M | 1.80M | 1.80M | |||
| Other Shareholders' Equity | 2.29M | 1.34M | 0.00 | 200.00K | 0.00 | |||
| Shares Outstanding | 207.12M | 205.77M | 187.90M | 184.40M | 176.90M | |||
| Tangible Book Value per Share | -2.26 | -2.21 | -1.57 | -0.58 | -0.11 | |||
| Total Shareholders' Equity | -468.56M | -455.53M | -294.60M | -107.00M | -19.30M | |||
| TOTAL LIABILITIES AND EQUITY | 491.25M | 516.96M | 550.00M | 588.20M | 334.70M | |||
| Statistics | ||||||||
| Debt/Equity | -1.70 | -1.79 | -2.49 | -5.47 | -14.22 | |||
| Current Ratio | 2.78 | 3.31 | 4.90 | 5.46 | 3.06 | |||
| Return On Assets (ROA) | -25.20% | -43.82% | -44.93% | -31.30% | -54.62% | |||
| Return On Equity (ROE) | N/A | N/A | N/A | N/A | N/A | |||
All data in USD , ROIC based on taxRate of 0.21